仁度生物(688193) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between -6.7 million and -10 million yuan, a decrease of 1,496 million to 1,826 million yuan compared to the same period last year, representing a year-on-year decline of 181% to 221%[3]. - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between -18.05 million and -21.35 million yuan, a decrease of 775 million to 1,105 million yuan compared to the same period last year[3]. - In the previous year, the net profit attributable to shareholders of the parent company was 8.2593 million yuan, while the net profit after deducting non-recurring gains and losses was -10.2985 million yuan[4]. Asset Impairment and Profit Impact - The company has recognized asset impairment losses and credit impairment losses based on prudence principles, impacting the current period's profit[5]. Revenue and Investment Growth - Despite macroeconomic challenges, the company achieved revenue growth and increased investment in new product development, contributing positively to profit[6]. - The company aims to further enhance its core competitiveness and expand its domestic and international market presence[6]. Earnings Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[7]. - The forecast data is preliminary and subject to final audited financial results to be disclosed in the 2024 annual report[8].